José Rodrigues Pereira

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Pasi A. Jänne, Alice T. Shaw, José Rodrigues Pereira et al. · The Lancet Oncology · 2012 · 654 citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +7

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · Journal of Clinical Oncology · 2004 · 262 citations

Ncic Ctg, Pharmacotherapy, Single Agent Activity +16

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

Pasi A. Jänne, Ian C. P. Smith, Gael McWalter et al. · British Journal of Cancer · 2015 · 74 citations · Full text

Do Current Lung Cancer Screening Guidelines Apply for Populations With High Prevalence of Granulomatous Disease? Results From the First Brazilian Lung Cancer Screening Trial (BRELT1)

Ricardo Sales dos Santos, Juliana Franceschini, Rodrigo Caruso Chate et al. · The Annals of Thoracic Surgery · 2015 · 56 citations

Epidemiology, Granulomatous Disease, Pulmonary Pathology +12

Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Mikhail Shtivelband, Ross A. Soo et al. · Journal of Clinical Oncology · 2015 · 43 citations · Full text